Evolutionary Distance Predicts Recurrence After Liver Transplantation in Multifocal Hepatocellular Carcinoma

Heits, Nils; Brosch, Mario; Herrmann, Alexander; Behrens, R; Röcken, Christoph; Schrem, Harald; Kaltenborn, Alexander; Klempnauer, Jürgen; Kreipe, Hans-Heinrich; Reichert, B.; Lenschow, Christina; Wilms, Christian; Vogel, Thomas; Wardelmann, Eva; Seehofer, Daniel; Buch, Stephan; Zeißig, Sebastian; Pannach, Sven; Raschzok, Nathanael; Dietel, Manfred; Schoenfels, Witigo von; Hinz, Sebastian; Teufel, Andreas; Evert, Matthias; Franke, André; Becker, Thomas; Braun, Felix; Schafmayer, Clemens

doi:10.1097/tp.0000000000002356

Cited by 4 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( 42 ) Despite a small sample size, authors validated their findings in an independent cohort. ( 42 ) In a study of 183 patients who received LT due to HCC, including patients before the implementation of Milan criteria, the fractional allelic imbalance (FAI) rate index was used to compare the acquired mutational load between different tumors. ( 43 ) The FAI was determined from the microdissected tissue site displaying the greatest amount of acquired allelic loss, and it was the strongest predictor of tumor recurrence followed by other clinicopathological parameters, such as vascular invasion, tumor number, or hepatic lobar involvement.…”

Section: Molecular Biomarkers For Hcc Risk Stratification In Ltmentioning

confidence: 82%

“…( 41 ) Likewise, in multinodular HCC, tumor evolutionary distance, which is a proxy for molecular dedifferentiation that is measured from genome‐wide single‐nucleotide polymorphism data between the cirrhotic liver and tumor nodules and between the tumor nodules themselves, is correlated with higher rates of recurrence and worse recurrence‐free survival. ( 42 ) Despite a small sample size, authors validated their findings in an independent cohort. ( 42 ) In a study of 183 patients who received LT due to HCC, including patients before the implementation of Milan criteria, the fractional allelic imbalance (FAI) rate index was used to compare the acquired mutational load between different tumors.…”

Section: Molecular Biomarkers For Hcc Risk Stratification In Ltmentioning

confidence: 85%

See 1 more Smart Citation

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Felden¹,

Villanueva

2020

Liver Transpl

View full text Add to dashboard Cite

Patient selection and organ allocation for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) relies predominantly on clinical parameters, such as tumor burden (ie, radiological imaging). Patients transplanted withinMilan criteria have outstanding outcomes with a 5-and 10-year survival of 70% and 55%, respectively. Tumor recurrence after transplantion is rare in these patients (10%); however, treatment options upon recurrence are generally limited, and outcomes are poor. There are also several studies showing how a subgroup of patients with tumors outside the Milan criteria might achieve comparable outcomes to patients within Milan criteria. In other words, the size and number of tumor nodules does not always reflect tumor biology, which could be better captured using molecular proxies for cancer aggressiveness. Over the last decade, we have significantly improved our understanding of the molecular landscape of early stage HCC. This includes the development of molecular classification, identification of prognostic and mutational signatures, and potential mechanisms of hepatocarcinogenesis. Some molecular markers have already proven useful to predict tumor-related outcomes in HCC patients after LT. Most of these analyses are limited to tissue-derived biomarkers, which limits their implementation in clinical practice because tissue biopsy is not required for HCC diagnosis. Minimally invasive alternative tools, such as liquid biopsy, are being increasingly explored and could help to individualize risk stratification for patients with HCC who will benefit from LT despite being outside the accepted clinical criteria.Liver Transplantation 26 823-831 2020 AASLD.

show abstract

Section: Molecular Biomarkers For Hcc Risk Stratification In Ltmentioning

confidence: 82%

Section: Molecular Biomarkers For Hcc Risk Stratification In Ltmentioning

confidence: 85%

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Felden¹,

Villanueva

2020

Liver Transpl

View full text Add to dashboard Cite

show abstract

“…The evolutionary distance measured from genome‐wide single nucleotide polymorphism (SNP) data was also a prognostic marker for survival; it was associated with the risk of recurrence of HCC and survival after transplantation ( p = .0002) 10 . Then, there was a correlation between SNPs of the WWOX gene and the prognosis of people with HCC.…”

Section: Resultsmentioning

confidence: 99%

“…The evolutionary distance measured from genome-wide single nucleotide polymorphism (SNP) data was also a prognostic marker for survival; it was associated with the risk of recurrence of HCC and survival after transplantation (p = .0002). 10 Then, there was a correlation between SNPs of the WWOX gene and the prognosis of people with HCC. AA+AG genotype and A allele of WWOX rs9926344 were associated with recurrent risk of HCC (p = .002 and p = .001, respectively), and the AA+AG genotype was an independent prognostic factor for tumour recurrence (HR 1.787…”

Section: Performance Of Genomics To Predict Patient Outcomementioning

confidence: 99%

Prognostic value of genotyping in hepatocellular carcinoma: A systematic review

Bodard

Liu

Guinebert

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Primary liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide in 2020, with approximately 906,000 new cases and 830,000 deaths. 1 Hepatocellular carcinoma (HCC) accounts for 75%-85% of cases, 1 and incidence rates continue to increase rapidly, by about 3% per year in women and 4% per year in men. 2 It is the fourth most common malignancy and the third leading cause of tumour-related death in China. 3 Owing to its highly aggressive nature, HCC is one of the deadliest primary cancers, with a 5-year survival rate of 10% or less. 4 Advances in sequencing technology have enabled a genome comprising more than 3 billion DNA base pairs, 5 to be sequenced within hours, 6 leading to widespread application for diagnosis and research. Cancer is a genetic disease resulting from an accumulation of mutations in a particular tissue causing uncontrolled cell division. Genomic medicine, sequencing DNA extracted from a tumour, constructs a picture of the mutational events and drivers for oncogenesis. 7 The poor prognosis of advanced HCC warrants this personalized.The objective of this article was to assess the value of genotyping for the prognostication or response to the treatment of HCC.

show abstract

“…In addition, TP53 mutations, high fractional allelic loss, hypomethylation of 8 tumour suppressors and absence of CTNNB1 mutations were of prognostic significance [85]. Lastly, tumour evolutionary distance by genome‐wide single‐nucleotide polymorphism genotyping was associated with recurrence and validated in a replication cohort [86].…”

Section: Chapter 1: Prognostic Biomarkers In Surgical Patients With Hccmentioning

confidence: 99%

Prognostic biomarkers in and selection of surgical patients with hepatocellular carcinoma

Pommergaard

2023

APMIS

View full text Add to dashboard Cite

Evolutionary Distance Predicts Recurrence After Liver Transplantation in Multifocal Hepatocellular Carcinoma

Abstract: Evolutionary distance allows for the determination of a high-risk group of recurrence if preoperative liver biopsy is considered.

Cited by 4 publications

References 46 publications

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Prognostic value of genotyping in hepatocellular carcinoma: A systematic review

Prognostic biomarkers in and selection of surgical patients with hepatocellular carcinoma

Contact Info

Product

Resources

About